Aurora Cannabis Inc. and MedReleaf Corp. officially announced that they have entered into a definitive agreement whereby Aurora will acquire all shares in MedReleaf Corp.
The transaction between these two Canadian companies is the largest deal in the cannabis sector to date, valued at C$3.2 billion.
In a press release issued earlier today, the companies highlighted “a total funded capacity of over 570,000 kg per year of high-quality cannabis, through nine facilities in Canada and two in Denmark,” and extensive distribution channels in Canada and internationally.
“The two companies have established distribution agreements with Alberta’s Alcanna (formerly Liquor Stores), Quebec’s SAQ, Pharmasave, and Shoppers Drug Mart in Canada, among others.
Additionally, the companies have a rapidly growing international footprint through a network of in-country sales and distribution capabilities and supply and licensing agreements on five continents, including countries such as Germany, Italy, Brazil, and Australia.”
A word from the CEOs
“This is a transformational transaction that brings together two pioneering cannabis companies, both committed to high technology, high quality, and low-cost production, to create a powerful platform for accelerated growth and success on a global scale,” said Terry Booth, CEO of Aurora.
Neil Closner, CEO of MedReleaf, added, “by combining with Aurora, an integrated producer with an exceptionally strong track record for execution, and deep domestic and international distribution capabilities, we will be ideally positioned to set the global standard for our industry at a pace that will be difficult to match.”
What this means for investors
Aurora is riding the wave of consolidation in anticipation of legalization this summer. The company entered into a C$1.23 acquisition deal with CanniMed Therapeutics Inc. earlier this year, as well as making a cornerstone investment and purchase order deal with The Green Organic Dutchman.
The Exchange Ratio for Aurora’s latest takeover will give 3.575 common shares of Aurora for each MedReleaf common share held. After the finalization of the merger transaction, “Aurora and MedReleaf shareholders would own approximately 61% and 39% of the pro forma company.”
MedReleaf shares are being valued at a premium of approximately 34%, at a price of C$29.44 per share.